SCHEMBL2177811

SCHEMBL2177811

CC(C(=O)O)N1Cc2ccc(-c3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)cc3)cc2C1=O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 5/20 0.53
DGAT1 O75907 6/20 0.51
MAPT P10636 3/20 0.50
HTT P42858 3/20 0.50
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
RAB9A P51151 1/20 0.50
SMN1; SMN2 Q16637 3/20 0.49
KDM4E B2RXH2 1/20 0.49
THRB P10828 1/20 0.48
CSGALNACT1 Q8TDX6 1/20 0.46
NTRK1 P04629 3/20 0.46
NTRK2 Q16620 3/20 0.46
AURKB Q96GD4 3/20 0.46
CSF1R P07333 2/20 0.46
KIT P10721 2/20 0.46
FLT1 P17948 2/20 0.46
EPHA2 P29317 2/20 0.46
FLT4 P35916 2/20 0.46
FLT3 P36888 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2181169 1.00 KDR (0.53) KDRDGAT1MAPTHTTMEN1
SCHEMBL2181413 0.93 DGAT1 (0.56) KDRDGAT1MAPTHTTMEN1
SCHEMBL2180531 0.93 DGAT1 (0.56) KDRDGAT1MAPTHTTMEN1
SCHEMBL2178379 0.91 KDR (0.52) KDRDGAT1MAPTHTTMEN1
SCHEMBL2179431 0.91 KDR (0.52) KDRDGAT1MAPTHTTMEN1
SCHEMBL2178373 0.91 KDR (0.52) KDRDGAT1MAPTHTTMEN1
SCHEMBL27894528 0.91 KDR (0.52) KDRDGAT1MAPTHTTMEN1
SCHEMBL2178195 0.90 DGAT1 (0.53) KDRDGAT1MAPTHTTMEN1
SCHEMBL2178663 0.90 DGAT1 (0.53) KDRDGAT1MAPTHTTMEN1
SCHEMBL2178369 0.88 DGAT1 (0.50) KDRDGAT1MAPTHTTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8748426-B2 Inhibitors of diacylglycerol acyl transferase Piramal Enterprises Limited (IN) 2014-06-10 US claimed
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Enterprises Limited (IN) 2012-11-15 US claimed
EP-2519500-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Healthcare Ltd. (IN) 2012-11-07 EP claimed
WO-2011080718-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-07-07 WO claimed
US-8748426-B2 Inhibitors of diacylglycerol acyl transferase Piramal Enterprises Limited (IN) 2014-06-10 US disclosed
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Enterprises Limited (IN) 2012-11-15 US disclosed
EP-2519500-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Healthcare Ltd. (IN) 2012-11-07 EP disclosed
WO-2011080718-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE DGAT1, DGAT2, LCAT KDR 4082/4885DGAT1 1/4885MAPT 116/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.